Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,910,224
  • Shares Outstanding, K 106,374
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ 45 M
  • EBITDA $ 42 M
  • 60-Month Beta 0.25
  • Price/Sales 6.14
  • Price/Cash Flow 48.70
  • Price/Book 7.14

Options Overview Details

View History
  • Implied Volatility 51.96% (+0.65%)
  • Historical Volatility 63.49%
  • IV Percentile 24%
  • IV Rank 14.92%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 25) 4.40 (9.58%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 165
  • Volume Avg (30-Day) 1,013
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 25,110
  • Open Int (30-Day) 41,394
  • Expected Range 41.54 to 50.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 3
  • High Estimate $-0.14
  • Low Estimate $-0.40
  • Prior Year $0.17
  • Growth Rate Est. (year over year) -276.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.00 +39.55%
on 03/24/26
50.40 -8.63%
on 03/25/26
+11.41 (+32.94%)
since 03/20/26
3-Month
28.66 +60.68%
on 02/19/26
50.40 -8.63%
on 03/25/26
+10.76 (+30.49%)
since 01/20/26
52-Week
28.66 +60.68%
on 02/19/26
91.00 -49.40%
on 10/08/25
-16.19 (-26.01%)
since 04/17/25

Most Recent Stories

More News
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

CORT Investors with Losses Encouraged to Contact Firm Before April 21 Deadline

CORT : 46.24 (+0.17%)
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT...

CORT : 46.24 (+0.17%)
Corcept 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 21, 2026 ...

CORT : 46.24 (+0.17%)
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know

Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know

TECH : 60.44 (+2.04%)
CORT : 46.24 (+0.17%)
SUPN : 51.19 (-0.39%)
PAHC : 56.81 (-0.46%)
RVTY : 93.05 (-0.97%)
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline

CORT : 46.24 (+0.17%)
Corcept Deadline: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

NEW YORK , April 16, 2026 /PRNewswire/ --

CORT : 46.24 (+0.17%)
Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 21, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...

CORT : 46.24 (+0.17%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).  ...

CORT : 46.24 (+0.17%)
3 Overrated Stocks That Concern Us

3 Overrated Stocks That Concern Us

CORT : 46.24 (+0.17%)
FORM : 145.03 (+5.70%)
AFRM : 66.59 (+3.24%)
INVESTOR NOTICE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Investor Class Action - Hagens Berman

SAN FRANCISCO , April 15, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April...

CORT : 46.24 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 48.99
2nd Resistance Point 47.77
1st Resistance Point 46.97
Last Price 46.24
1st Support Level 44.95
2nd Support Level 43.73
3rd Support Level 42.93

See More

52-Week High 91.00
Fibonacci 61.8% 67.19
Fibonacci 50% 59.83
Fibonacci 38.2% 52.47
Last Price 46.24
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.